Stryker Corporation 10-Q Summary: Q1 2003
Business Context and Reporting Period
This filing covers the quarterly period ended March 31, 2003. Stryker Corporation operates in two primary reportable segments: Orthopaedic Implants (reconstructive, trauma, and spinal implants) and MedSurg Equipment (powered surgical instruments, endoscopic systems, and hospital beds). The company also reports "Other" activities, primarily Physical Therapy Services and corporate administration.
Key Financial Metrics
| Metric | Q1 2003 | Q1 2002 | Change |
|---|---|---|---|
| Net Sales | $846.9 million | $702.9 million | +20% |
| Gross Profit | $546.1 million | $448.0 million | +22% |
| Gross Margin | 64.5% | 63.7% | +0.8 pts |
| Net Earnings | $104.1 million | $81.1 million | +28% |
| Diluted EPS | $0.51 | $0.40 | +28% |
| Operating Cash Flow | $104.2 million | $62.7 million | +66% |
| Total Debt (Outstanding) | $448.9 million | N/A | - |
| Cash & Equivalents | $39.6 million | N/A | - |
Material Changes vs. Prior Period
- Sales Growth: Net sales increased 20% year-over-year. Growth was driven by an 11% increase in unit volume/mix, a 5% favorable foreign currency impact, 2% price increases, and 2% from acquisitions.
- Segment Performance: Orthopaedic Implants sales rose 24% to $490.8 million. MedSurg Equipment sales rose 18% to $304.1 million. International sales grew 27% (11% excluding currency).
- Expense Trends: R&D expenses increased 29% to $43.2 million due to new product development focus. SG&A expenses rose 22% to $337.5 million, partly due to higher commissions and a $3.8 million increase in insurance costs.
- Interest & Taxes: Interest expense declined to $7.0 million (from $10.6 million) due to lower debt balances and rates. The effective tax rate decreased to 31.0% (from 33.0%) due to increased manufacturing in lower-tax jurisdictions.
Outlook, Risks, and Unusual Items
- Liquidity: Working capital increased to $516.0 million. The company has $638.5 million in additional borrowing capacity. On April 24, 2003, the accounts receivable securitization facility was increased from $130.0 million to $200.0 million.
- Acquisitions: The company is integrating the Surgical Dynamics Inc. (SDI) spinal implant business acquired in July 2002. This resulted in increased intangible amortization ($9.0 million vs $6.0 million in 2002).
- Insurance: A wholly-owned captive insurance company was established in January 2003 to manage self-insured product liability retention limits.
- Risks: Forward-looking statements highlight risks including regulatory cost-containment measures, changes in third-party reimbursement levels, product liability claims, and foreign exchange fluctuations.
- Dividends: No cash dividends were declared during Q1 2003. A dividend of $0.12 per share was paid in January 2003 for the Q4 2002 record date.
Investor Verification Checklist
- Inventory Levels: Verify the 12-day increase in "Days Sales in Inventory" (to 138 days) to ensure it is not indicative of slowing demand or obsolescence.
- Foreign Currency Impact: Assess the sustainability of the 5% sales growth and $36.7 million favorable currency impact given the volatility of exchange rates.
- Insurance Costs: Monitor the $3.8 million increase in insurance costs and the performance of the new captive insurance company.
- Debt Maturity: Review the $250.0 million revolving credit agreement expiring in December 2003 and the company's refinancing strategy.
- Pro Forma EPS: Note that pro forma EPS (under FASB 123) was $0.49, compared to reported $0.51, reflecting the impact of stock-based compensation.